Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Medicine, Lymphoma, Internal medicine, Brentuximab vedotin, Oncology, and Hodgkin lymphoma.
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era
PET Response and Outcome in Low‐Risk Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1
Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium’s phase 2 study cHOD17 (NCT03755804).
Langerhans Cell Histiocytosis in Cardiofaciocutaneous Syndrome
Pediatric Hodgkin Consortium Trial Updates: Response-based omission of radiotherapy (RT) for the majority of young people with Hodgkin lymphoma (HL) while maintaining excellent outcomes: Five-year results of HOD08 for low-risk (LR) HL and initial results of cHOD17 high-risk (HR) stratum
The Post-transplant Lymphoproliferative Disorders—Metagenomic Shotgun Microbial Sequencing (PTLD-MSMS) Study Methods and Protocol
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
Outcomes in pediatric relapsed/refractory anaplastic large cell lymphoma: A multi-institutional retrospective analysis.
Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric <scp>PTLD</scp> collaborative
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders
Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
Pediatric EBV-negative monomorphic post–solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.
Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Preclinical evaluation of XPO1 inhibition in Wilms tumors.
Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma